In patients with tyr1248 Her-2/neu phosphorylation, the median (95% CI) progression-free survival calculated from survival curves was 11.7 (95% CI 5.2–18.3) months and thus significantly longer as compared to the median (95% CI) progression-free survival of 4.5 (3.4–5.6) months observed in patients without pHer-2/neu staining tumours (log-rank test: P<0.0095). Here, ERBB2 is linked to neoplasm.